Intravenous iron: From anathema to standard of care

American Journal of Hematology

Volumn 83, Issue 7, 2008, Pages 580-588

  Auerbach, Michael ^a,b   Coyne, Dan ^c   Ballard, Harold ^d  

^a Division of Hematology and Oncology   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANTINEOPLASTIC AGENT; CIMETIDINE; DIPHENHYDRAMINE; ERYTHROPOIETIN; FERRIC GLUCONATE; FERRIC HYDROXIDE; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS GLUCONATE; FERROUS SULFATE; HEPCIDIN; IRON; IRON DEXTRAN; IRON SACCHARATE; METHYLPREDNISOLONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARACETAMOL; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ALBUMINURIA; ANAPHYLAXIS; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; HEADACHE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPOTENSION; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON THERAPY; LEG PAIN; MENINGISM; MONOTHERAPY; MUSCULOSKELETAL STIFFNESS; MYALGIA; NEOPLASM; NONCARDIAC CHEST PAIN; NONHUMAN; PAIN; PERIORBITAL EDEMA; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RESPIRATORY DISTRESS; SARCOMA; SKIN DISCOLORATION; STIFF NECK; STRIDOR; TACHYCARDIA; TACHYPNEA; UNSPECIFIED SIDE EFFECT; URTICARIA; WHEEZING;

ANEMIA; ANIMALS; CHRONIC DISEASE; HUMANS; INJECTIONS, INTRAVENOUS; IRON; METHYLPREDNISOLONE; NEOPLASMS;

EID: 45749083839     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21154     Document Type: Article

References (75)

1. Stockman R. The treatment of chlorosis with iron and some other drugs. Br Med J 1893;1:881-885.
2. Blaud P. Sur les maladies chloropiques et sur un mode de traitement specifique dons ces affecions. Rev Med Fr Etrang 1832;45:357-367.
3. Heath CW, Strauss MB, Castle WB. Quantitative aspects of iron deficiency in hypochromic anemia. J Clin Invest 1932;11:1293-1312.
4. Goetsch AT, Moore CV, Minnich V. Observations on the effects of massive doses of iron given intravenously to patients with hyperchromic anemia. Blood 1946;1:129-142.
5. Nissim JA. Intravenous administration of iron. Lancet 1947;1:49-51.
6. Baird IM, Podmore DA. Intra-muscular iron therapy in iron deficiency anemia. Lancet 1954;2:942.
7. Maslovsky I. Intravenous iron in a primary-care clinic. Am J Hematol 2005;78:261-264.
8. Umbreit J. Iron deficiency: A concise review. Am J Hematol 2005;78:225-231.
9. Petersdorf RG. Harrison's Principles of Internal Medicine. McGraw-Hill; 1983.
10. Kanakaraddi VP, Hoskatti CG, Nadig VS, et al. Comparative therapeutic study of T.D.I. and I.M. injections of iron dextran complex in anaemia. J Assoc Phys India 1973;21:849-653.
11. Grasso P. Sarcoma after intramuscular iron injection. Br Med J 1973;2:667.
12. Greenberg G. Sarcoma after intramuscular iron injection. Br Med J 1976;3:1508-1509.
13. Auerbach M, Ballard H, Glaspy J. Clinical update: Intravenous iron for anaemia. Lancet 2007;369:1502-1504.
14. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980;243:1726-1731.
15. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004;15(Suppl 2):S93-S98.
16. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004;65:2279-2289.
17. Auerbach M, Witt D, Toler W, et al. Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 1988;111:566-570.
18. Shuttleworth D, Spence C, Slade R. Meningism due to intravenous iron dextran. Lancet 1983;2:453.
19. Auerbach M, Chaudhry M, Goldman H, Ballard H. Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: A double blind randomized trial. J Lab Clin Med 1998;131:257-260.
20. U.S.Renal Data System. USRDS 1991 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1991.
21. Mast AE, Blinder MA, Dietzen DJ. Reticulocyte hemoglobin content. Am J Hematol 2007; e-pub ahead of print.
22. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-78.
23. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995;26:41-46.
24. Fishbane S, Ungureanu VD, Maesaka JK, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996;28:529-534.
25. Rodgers GM III, Cella D, Chanan-Khan A, et al. Cancer- and treatment-related anemia. J Natl Compr Canc Netw 2005;3:772-789.
26. Barton JC, Barton EH, Bertoli LF, et al. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral Iron supplementation. Am J Med 2000;109:27-32.
27. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 2001;37:S182-S238.
28. Coyne DW. Iron Indices: What do they really mean? Kidney Int 2006;69:S4-S8.
29. Auerbach M, Winchester J, Wahab A, et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis 1998;31:81-86.
30. Case G. Maintaining iron balance with total-dose infusion of intravenous iron dextran. ANNA J 1998;25:65-68.
31. Mamula P, Piccoli DA, Peck SN, et al. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002;34:286-290.
32. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999;33:464-470.
33. Michael B, Coyne DW, Fishbane S, et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int 2002;61:1830-1839.
34. Coyne DW, Adkinson NF, Nissenson AR, et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 2003;63:217-224.
35. Silverberg DS, Iaina A, Peer G, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 1996;27:234-238.
36. Aronoff GR, Bennett WM, Blumenthal S, et al. Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens. Kidney Int 2004;66:1193-1198.
37. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 2001;38:988-991.
38. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004;19:1571-1575.
39. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378-382.
40. Fletes R, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001;37:743-749.
41. McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran - A comparison of two products. Am J Nephrol 2000;20:455-462.
42. Critchley J, Dundar Y. Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): A systematic review. Transfus Alternat Transfus Med 2007;9:8-36.
43. Moniem KA, Bhandari S. Tolerabillty and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations. Transfus Alternat Transfus Med 2007;9:37-42.
44. Sav T, Tokgoz B, Sipahioglu MH, et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail 2007;29:423-426.
45. Van Wyck DB, Cavallo G, Spinowitz BS, et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 2000;36:88-97.
46. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
47. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
48. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer pat ents receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
49. Henry D, Abels R, Larholt K. Prediction of response to recombinant human erythropoietin (r-HuEPO/epoetin-α) therapy in cancer patients. Blood 1995;85:1676-1678.
50. Abels RI, Larholt KM, Krantz KD, Bryant EC. Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. Oncologist 1996;1:140-150.
51. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-1307.
52. Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin β increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia 2007;21:627-632.
53. Kim YT, Kim SW, Yoon BS, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007;105:199-204.
54. Pinter T, Mossman T, Suto J, Vansteenkiste J. Effects of intravenous (IV) iron supplementation on responses to every-3-week (Q 3W) darbepoetin α (DA) by baseline hemoglobin in patients (pts) with chemotherapy-induced anemia (CIA). ASCO Annual Meeting Proceedings, 2007. J Clin Oncology 2007;25:9106 (abstract).
55. Andrews NC. The iron transporter DMT1. Int J Eiochem Cell Biol 1999;31:991-994.
56. Ludwiczek S, Aigner E, Theurl I, Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003;101:4148-4154.
57. Pietrangelo A. Physiology of iron transport and the hemochromatosis gene. Am J Physiol Gastrointest Liver Physiol 2002;282:G403-G414.
58. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-1276.
59. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003;33:21-22.
60. Goodnough LT, Marcus RE. Erythropoiesis in patients stimulated with erythropoietin: The relevance of storage iron. Vox Sang 1998;75:128-133.
61. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin α versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-242.
62. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy related anemia without iron deficiency treated with darbepoetin α. J Clin Oncol, in press.
63. Scheiber-Mojdehkar B, Lutzky B, Schaufler R, et al. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: No correlation to peroxide generation. J Am Soc Nephrol 2004;15:1648-1655.
64. Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004;15:1623-1632.
65. Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3070-3080.
66. Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 2002;57:457-461.
67. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002;40:90-103.
68. Agarwal R, Rizkala AR, Kaskas MO, et al. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int 2007;72:638-642.
69. Pai AB, Boyd AV, McQuade CR, et al. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 2007;27:343-350.
70. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol 2007;18:975-984.
71. Singh AK, Coyne DW, Shapiro W, Rizkala AR. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 2007;71:1163-1171.
72. Auerbach M, Rodgers GM. Intravenous iron. N Engl J Med 2007;357:93-94.
73. Agarwal R, Rizkala AR, Bastani B, et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006;26:445-454.
74. Henry DH, Dahl NV;Study Group GTFC. Does quality of life improvement precede anemia correction in patients with chemotherapy-induced anemia treated with intravenous iron? J Clin Oncol (Meeting Abstracts) 2007;25:9082.
75. Cavill I, Auerbach M, Bailie GR, et al. Iron and the anaemia of chronic disease: A review and strategic recommendations. Curr Med Res Opin 2006;22:731-737.